Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma
© Shi et al.; licensee BioMed Central Ltd. 2013
Received: 19 January 2013
Accepted: 9 May 2013
Published: 24 May 2013
Epithelial-mesenchymal transition (EMT) is defined as switching of polarized epithelial cells to a migratory fibroblastoid phenotype. EMT is known to be involved in the progression and metastasis of various cancers. The aim was to evaluate that whether EMT-related proteins' alterations are associated with clinicopathological features and prognosis in lung adenocarcinoma.
The expression of EMT-related proteins including cytokeratin, E-cadherin, TTF-1, β-catenin, vimentin, Snail, Twist, CD44 was evaluated by immunohistochemistry using a tissue array method in the lung adenocarcinoma tissues of 95 patients. In addition, clinicopathological characteristics and survival were compared with the expression of EMT-related proteins.
Loss of epithelial proteins and/or acquisition of the expression of mesenchymal proteins were observed in lung adenocarcinoma. These proteins’ alteration was associated with poor cell differentiation and poor patients’ outcome, respectively. Subjects were divided into two groups according to the number of EMT-related proteins’ alteration. A higher number of EMT-related proteins’ alteration was found to be significantly associated with unfavorable outcome. Multivariate analysis showed that a higher number of EMT-related proteins’ alteration was independently associated with poor prognosis.
The number of EMT-related proteins’ alteration is a significant prognostic marker to predict overall survival in patients with lung adenocarcinoma. The information generated will be valuable for the prognosis of patients with lung adenocarcinoma.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1007838329872974
KeywordsEpithelial–mesenchymal transition Lung adenocarcinoma Survival analysis Tissue array analysis
Non-small cell lung cancer is the leading cause of cancer death worldwide. Among non–small cell lung cancer variants, adenocarcinoma is the most common histological subtype. Surgical resection is the treatment of choice for early-stage adenocarcinoma. However, tumor recurrence and metastasis are the most common events encountered after resection that lead to mortality [1, 2]. Chemotherapy and radiotherapy are common treatment modalities applied to patients with recurrent adenocarcinoma , but the combination modality did not significantly improve patients’ survival. Since tumor metastasis is the main obstacle for long-term survival after surgical resection, identification of molecular markers related to metastasis may better predict the prognosis in patients with lung adenocarcinoma.
Epithelial-mesenchymal transition (EMT) consists of a rapid and often reversible change of cell phenotype. During EMT, cells lose or redistribute epithelial proteins and acquire mesenchymal proteins. As a result, cells loss epithelial polarity and acquire a spindle-shaped, highly motile fibroblastoid phenotype. This transition involves which confer upon cells the ability to pass through the basement membrane [4–7] and a developmental program of tumor cells [8, 9]. The phenomenon of EMT is proved during various of numerous cancers, e.g. pancreatic cancer, gastric, and colorectal carcinomas [10–13]. It is an important event in the progression, invasion and metastasis of carcinomas which have a particularly dismal prognosis [5, 7, 14].
In this study, using a tissue array method, we investigated the expression of known EMT-related proteins including cytokeratin, E-cadherin, TTF-1, β-catenin, vimentin, Snail, Twist, CD44 in lung adenocarcinoma patients’ samples. The aim was to evaluate changes in EMT-related protein and to investigate their association with clinicopathological parameters and prognosis in lung adenocarcinoma.
Materials and methods
From January 2007 to December 2009, 95 patients undergoing surgical resection for lung adenocarcinoma at Nanjing Drum Tower Hospital were enrolled in this study. Clinicopathological parameters such as age, gender, cell differentiation and pathological stage were evaluated by reviewing pathological records. The mean patient age was 58 years. Samples were obtained from 56(58.8%) male and 39 (41.2%) female patients, and there were 51 (53.7%, I-II stage) cases of early-stage adenocarcinoma and 44 (46.3%, III-IV stage) cases of advanced-stage adenocarcinoma. Thirty-three patients (34.7%) were poorly differentiated adenocarcinoma and sixty-two (65.3%) were well and moderately differentiated adenocarcinoma. Outcomes were determined from the date of surgery until death or June 2012. The study was approved by the Medical Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School.
Tissue microarray construction
The tissue microarray was created from tissue blocks that had been stored at approximately 24°C. Hematoxylin and eosin-stained sections were reviewed to select representative areas of tumor, and then to acquire cores for the microarray. The tissue microarray block was constructed with a precision instrument (Beecher Instruments, Sun Prairie, WI). Core tissue biopsies (1 mm in diameter) were taken from individual donor blocks and arranged in a new recipient beeswax block (tissue array block). Sections (2 μm) were consecutively cut and placed on positively charged slides for use in immunohistochemical staining.
Immunohistochemical staining, scoring
Antibodies used in the immunohistochemical study
Altered expression in cancer
mouse monoclonal, clone AE1/AE3, 1:200, Dako
mouse monoclonal, clone HECD-1, 1:200, Zymed
mouse monoclonal, clone 8G7G3/1, 1:200, Dako
mouse monoclonal, clone CAT-5H10, 1:500, Zymed
Cytoplasmic or Nuclea
mouse monoclonal, clone vim-3B4, 1:400, Dako
rabbit polyclonal, ab 85931, 1:500, Abcam
rabbit polyclonal, ab 50581, 1:500, Abcam
mouse monoclonal, clone DF1485, 1:250, Dako
Comparison of the variables was performed using Student’s t test, Fisher’s exact test or Pearson’s χ2 test, depending on the nature of the data. Correlation analysis was performed using Spearman’s correlation analysis. Survival curves were estimated using the Kaplan–Meier product-limit method, and the significance of differences between survival curves was determined using the log rank test. Multivariate analysis was performed by Cox proportional hazards regression modeling. All statistical tests were two-sided, and statistical significance was accepted at the p < 0.05 level. All analyses were performed using SPSS version 11.0.
The alteration of EMT-related proteins and their correlation with clinicopathological factors in lung adenocarcinoma
Association between EMT-related proteins and clinicopathological variables
Well and moderately
Loss of epithelial protein expression
Acquisition of mesenchymal protein expression
The association between epithelial protein and mesenchymal protein expression was demonstrated by the Pearson χ2 test. Losing of cytokeratin and E-cadherin were significantly associated with β-catenin (p = 0.029, p < 0.001) and Twist (p = 0.006, p = 0.028) expression. Losing of TTF-1 was found to be significantly associated with β-catenin (p = 0.006) and vimentin (p = 0.026) expression.
The alteration of EMT-related proteins as prognostic factors in patients with lung adenocarcinoma
Univariate analysis for overall survivals of 95 patients with lung adenocarcinoma
Multivariate analyses for overall survivals of 95 patients with lung adenocarcinoma
0.399(0.241 to 0.659)
1.772(1.056 to 2.974)
Well and moderately
0.430(0.255 to 0.726)
Patients with EMT-N2 showed a more unfavorable prognosis than those with EMT-N1, and this was true for early-stage lung adenocarcinoma (stage I and II, n = 51). For early-stage lung adenocarcinoma in the study, patients with EMT-N2 had significantly worse overall survival than those with EMT-N1 (p = 0.0001, Figure 2B). Multivariate analysis identified EMT-N was also an independent prognostic marker for overall survival in early-stage lung adenocarcinoma (HR = 0.405, 95% CI = 0.180 to 0.908, p = 0.028).
Non-small cell lung cancer (NSCLC) is the most predominant type of lung cancer and the leading cause of cancer death worldwide . Deletions or insertions in exon 19 and point mutations in exons 18 and 21 in the epidermal growth factor receptor are special diagnostic value in advanced-stage non-small cell lung cancer patients [17, 18]. Expression of oncofetal protein IMP3 correlates with distant metastases regardless of histological subtype of lung adenocarcinoma . Promoter methylation was associated with clinicopathologic characteristics and may be served as a potentially increased risk factor for pleural indentation of NSCLC . These groups have used different sets of markers to predict the prognosis and survival of patients with NSCLC with some success. However, there is little by using a combination of metastasis-related markers. Epithelial-mesenchymal transition (EMT) is considered to be one of the major molecular mechanisms inducing tumour invasion and metastasis. Some study showed that centrally located tumour cells stained positively for epithelial markers, but it was absent at the invasive front of the tumour in lung cancer [21–23]. So the expression of EMT-related proteins which related to metastasis may better reflect and predict the prognosis and survival in patients with NSCLC. In our study the aim was to evaluate changes in EMT-related proteins and to investigate their association with prognosis in lung adenocarcinoma.
As the epithelial markers, E-cadherin and cytokeratin expression is strongly related to positive serosal involvement, infiltrating type, poorly differentiated histology [13, 24]. Thyroid transcription factor-1 (TTF-1) is a transcription factor that is expressed in approximately 75% of lung adenocarcinoma. Several studies demonstrated an independent lower risk of death for lung adenocarcinoma patients whose tumor expresses positive TTF1 staining . Recently one paper suggested that TTF-1 is an important EMT-related marker. It inhibits EMT and restores epithelial phenotype in lung adenocarcinoma cells . As a result, a novel aspect of TTF-1 is that losing expression of TTF-1 made tumor cells generating EMT and then resulting in the worse prognosis of patients. The above reports and our findings indicate that loss of E-cadherin, cytokeratin and TTF1 expression is an important indicator of EMT. The regulators involving mesenchumal differentiation such as β-catenin, Snail, Twist are considered to regulate EMT by strong repression of E-cadherin expression [11, 27, 28]. Our study showed that the acquisition of mesenchymal protein expression tended to correlate with loss of epithelial protein expression. CD44 has been identified as a specific marker of cancer stem cells. In addition, CD44 plays an important role in tumor cells undergoing an EMT-like process and associated with cancer progression [29, 30]. In the present study we have demonstrated that the expression of various EMT-related proteins is associated with a poor prognosis in lung adenocarcinoma. Our results support previous reports where the expression of various EMT-related molecule were associated with neoplastic progression and poor survival in some malignancies.
Characteristics of EMT include complete loss of epithelial polarity, loss of epithelial markers and acquisition of mesenchymal markers. In addition to processes involving complete EMT, many processes occurring during development and in adult organisms involve only a transient loss of epithelial polarity without full acquisition of mesenchymal characteristics. We have defined as partial EMT [31, 32]. Partial EMT has been suggested to occur in some metastatic cancers and the number of EMT-related proteins’ alteration may reflect the degree of EMT in a way . So in our study, we divided the patients into two groups according to the number of EMT-related proteins’ alteration. The results showed that the patients with higher number of EMT-related proteins’ alteration had a significantly shorter overall survival. In multivariate analyses the number of EMT-related proteins’ alteration was significant independent prognostic indicators for overall survivals. This finding suggests that higher number of EMT-related proteins’ alteration may be significantly related to tumor progression and metastasis.
There is increasing evidence to support the role of postoperative adjuvant chemotherapy in locally advanced-stage lung cancer. However, the effect of adjuvant chemotherapy in early-stage adenocarcinoma remains to be determined . In the study we analyzed the predictive ability of the number of EMT-related proteins’ alteration in patients with early-stage lung adenocarcinoma. For early-stage lung adenocarcinoma (stage I and II) there is a trend toward worse overall survival in patients with a higher number of EMT-related proteins’ alteration. The number of EMT-related proteins’ alteration was significant independent prognostic indicators for overall survivals for early-stage adenocarcinoma in multivariate analyses. The results suggest that the number of EMT-related proteins’ alteration may be able to identify the poor prognostic cases in early-stage lung adenocarcinoma. Adjuvant therapy may be considered in patients with early-stage lung adenocarcinoma when patients have a higher number of EMT-related proteins’ alteration.
The present study showed mainly two results. One was that the number of EMT-related proteins’ alteration is a independent prognostic marker to predict overall survival in patients with lung adenocarcinoma. The information generated will be valuable for the prognosis of patients with lung adenocarcinoma. The other was that the number of EMT-related proteins’ alteration is also a independent prognostic marker to predict overall in patients with early-stage (stage I and II) lung adenocarcinoma. The information generated will be valuable for determining the adjuvant chemotherapy for patients with early-stage lung adenocarcinoma.
Written informed consent was obtained from the patient for publication of this report and any accompanying images.
The authors wish to thank all the patients and workmates who took part in this study.
- Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, Pairolero PC, Deschamps C, Yang P: Predicting postrecurrence survival among completely resected non small-cell lung cancer patients. Ann Thorac Surg. 2006, 81: 021-027. 10.1016/j.athoracsur.2006.01.081.View Article
- D’Amico TA: Molecular biologic staging of lung cancer. Ann Thorac Surg. 2008, 85: S737-S742. 10.1016/j.athoracsur.2007.11.047.View ArticlePubMed
- Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC: Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007, 83: 409-417. 10.1016/j.athoracsur.2006.08.046.View ArticlePubMed
- Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N: Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003, 22: 7155-7169. 10.1038/sj.onc.1206887.View ArticlePubMed
- Gupta GP, Massague J: Cancer metastasis: building a framework. Cell. 2006, 127: 679-695. 10.1016/j.cell.2006.11.001.View ArticlePubMed
- Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004, 566: 9-20. 10.1016/S1383-5742(03)00033-4.View ArticlePubMed
- Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006, 172: 973-981. 10.1083/jcb.200601018.PubMed CentralView ArticlePubMed
- Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol. 2009, 174: 1588-1593. 10.2353/ajpath.2009.080545.PubMed CentralView ArticlePubMed
- Kang Y, Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004, 118: 277-279. 10.1016/j.cell.2004.07.011.View ArticlePubMed
- Nishioka R, Itoh S, Gui T, Gai Z, Oikawa K, Kawai M, Tani M, Yamaue H, Muragaki Y: SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol. 2010, 89: 149-157. 10.1016/j.yexmp.2010.05.008.View ArticlePubMed
- Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, Sarbia M, Carneiro F, Becker KF: Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol. 2007, 211: 507-515. 10.1002/path.2138.View ArticlePubMed
- Bukholm IK, Nesland JM, Borresen-Dale AL: Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol. 2000, 190: 15-19. 10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-L.View ArticlePubMed
- Kang H, Min BS, Lee KY, Kim NK, Kim SN, Choi J, Kim H: Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol. 2011, 18: 711-719. 10.1245/s10434-010-1338-z.View ArticlePubMed
- Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454. 10.1038/nrc822.View ArticlePubMed
- Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovács AF, Stauber RH: Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007, 211: 532-540. 10.1002/path.2134.View ArticlePubMed
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.View ArticlePubMed
- Uruga H, Kishi K, Fujii T, Beika Y, Enomoto T, Takaya H, Miyamoto A, Morokawa N, Kurosaki A, Yoshimura K: Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med. 2010, 49: 103-107. 10.2169/internalmedicine.49.2531.View ArticlePubMed
- Otto C, Csanadi A, Fisch P, Werner M, Kayser G: Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol. 2012, 7: 146-10.1186/1746-1596-7-146.PubMed CentralView ArticlePubMed
- Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 2012, 7: 165-10.1186/1746-1596-7-165.PubMed CentralView ArticlePubMed
- Ji M, Zhang Y, Shi B, Hou P: Association of promoter methylation with histologic type and pleuralindentation in non-small cell lung cancer (NSCLC). Diagn Pathol. 2011, 6: 48-10.1186/1746-1596-6-48.PubMed CentralView ArticlePubMed
- Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ: Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009, 64: 1082-1089. 10.1136/thx.2009.115691.View ArticlePubMed
- Tischler V, Pfeifer M, Hausladen S, Schirmer U, Bonde AK, Kristiansen G, Sos ML, Weder W, Moch H, Altevogt P, Soltermann A: L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mo Cancer. 2011, 10: 127-137. 10.1186/1476-4598-10-127.View Article
- Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, Wu CW: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial- mesenchymal transdifferentiation. Cancer Res. 2010, 70: 10433-10444. 10.1158/0008-5472.CAN-10-2638.View ArticlePubMed
- Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004, 4: 118-132. 10.1038/nrc1276.View ArticlePubMed
- Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR: Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009, 13: 1977-1986. 10.1111/j.1582-4934.2008.00594.x.PubMed CentralView ArticlePubMed
- Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T, Miyazono K: Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial- to- mesenchymal transition in lung adenocarcinoma cells. Cancer Res. 2009, 69: 2783-2791. 10.1158/0008-5472.CAN-08-3490.View ArticlePubMed
- Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA: The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005, 8: 197-209. 10.1016/j.ccr.2005.07.009.View ArticlePubMed
- Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR: The prognostic impact of protein expression of E-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. 2010, 2010: 616023-PubMed CentralView ArticlePubMed
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.PubMed CentralView ArticlePubMed
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.PubMed CentralView ArticlePubMed
- Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003, 4: 657-665. 10.1038/nrm1175.View ArticlePubMed
- Huber MA, Kraut N, Beug H: Molecular requirements for epithelial -mesenchymal transition during tumor progression. Curr Opin Cell Bio. 2005, l17: 548-558.View Article
- Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005, 5: 675-688.View ArticlePubMed
- Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008, 26: 5043-5051. 10.1200/JCO.2008.16.4855.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.